RACHEL FILZER: Open Payments
NPI 1144588476 · DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,101 in 29 payments from 7 companies in 2025. Trend: 2023 $954 · 2024 $1,237 · 2025 $1,101
Food & beverage: $1,101
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $304 |
| Otsuka America Pharmaceutical, Inc. | 13 | $234 |
| Teva Pharmaceuticals USA, Inc. | 3 | $136 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| ABBVIE INC. | 2 | $121 |
| Lundbeck LLC | 2 | $96 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $88 |
Products named: CAPLYTA, REXULTI, ABILIFY MAINTENA, COBENFY, VRAYLAR, UZEDY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
